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INTRODUCTION
Colorectal cancer (CRC) is the third most 
common cancer in the UK and the second 
biggest cancer killer.1 There are now 
organised cancer screening programmes 
in most countries across Europe and North 
America, including the UK,2 although the 
vast majority of CRCs are still diagnosed 
in response to symptoms.3,4 Even high-
risk symptoms — outlined in Box 1, which 
summarises guidance for GPs who suspect 
patients of having CRC — only have a positive 
predictive value of 3–4%, meaning that the 
vast majority of patients who undergo an 
investigation will not have cancer.5,6
For patients who can tolerate the 
procedure, colonoscopy is the current 
gold-standard test to rule out and detect 
CRC; it is accessed via the fast-tracked 
2-week wait (2WW) pathway; that is, the 
maximum wait-time target in the UK for 
patients with suspected cancer to be first 
seen by a specialist in secondary care.7,8 
Notwithstanding the potential human cost 
of an invasive procedure, colonoscopy could 
miss up to 10% of cancers and carries a 
small risk of complications.9 In addition, 
currently, colonoscopy resources in the 
UK are stretched to their limits.10–12 The 
Achieving World-Class Cancer Outcomes 
cancer strategy 2015–2020 advocates 
increased access for GPs to diagnostic 
point-of-care tests in primary care;13 
however, only about half of patients with 
CRC receive a test in primary care before an 
urgent referral for suspected CRC.14
In July 2017, the National Institute for 
Health and Care Excellence (NICE) updated 
the Suspected Cancer: Recognition and 
Referral guideline (NG12) by publishing a 
new diagnostic guidance (DG30).15 DG30 
recommended that a quantitative faecal 
immunochemical test (FIT) be used as a 
primary care triage test for patients with 
‘low risk but no risk’; that is, patients who 
do not meet the 2WW referral criteria.5 
There has also been interest in using a 
FIT as a rule-out test for patients with 
high-risk symptoms of CRC who do qualify 
for 2WW referral, based on its negative 
predictive value range of 99.8–100% with 
a threshold of 10 mg faecal haemoglobin 
(FHb) with a single sample.15,16 The potential 
recommendation is being investigated in 
ongoing studies.17,18 So far, clinical studies 
suggest that low or undetectable FHb may 
rule out significant bowel disease,19,20 and 
a recent systematic review concluded that 
approximately 75% of patients who are 
symptomatic could avoid colonoscopy if 
triaged beforehand with a FIT.21
If a FIT is implemented in primary care 
as a rule-out test for patients who have 
high-risk CRC symptoms, it could reduce 
the need for a 2WW referral for patients 
who receive a negative test result, and 
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patients would benefit compared with having a 
colonoscopy (OR 2.02 [95% CI = 1.46 to 2.79]); 
and were highly confident about discussing 
the benefits of a FIT (OR 2.14 [95% CI = 1.46 
to 3.16]). GPs were less willing if they had had 
>10 urgent referrals in the past year (OR 0.62 
[95% CI = 0.40 to 0.94]) and thought that longer 
consultations would be needed (OR 0.61 [95% 
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The study findings suggest that the acceptability 
of using a FIT as a rule-out test in primary care 
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perceived the test to be accurate preferring it over 
colonoscopy. Any potential guideline changes 
recommending a FIT in patients with high-risk 
symptoms, instead of urgent referral to rule out 
CRC, are likely to require intensive supporting 
educational outreach to increase GP confidence 
in the accuracy and application of a FIT in this 
context.
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reduce the pressure on colonoscopy 
services.16,19,22,23 However, little is known 
about how GPs would use a FIT as a rule-
out test of CRC and the acceptability of the 
test kit. Successful adoption of the FIT in 
primary care, therefore, will rely on GPs’ 
attitudes about the test and their role in 
implementing its use. The aim of this online 
survey was to identify the attitudes and 
beliefs of UK GPs regarding use of a FIT 
as a rule-out test in order to inform clinical 
decision makers during implementation of 
the FIT in primary care. The survey included 
questions on:
• existing awareness and use of a FIT as a 
rule-in test; 
• attitudes and beliefs towards the FIT; 
• GP demographics; and 
• practice characteristics. 
METHOD
Study design and sample
In December 2017, 14 100 GPs from England 
were invited to take part in a 10-minute 
online survey using M3 Global Research’s 
panel of GP workforce via https://www.
doctors.net.uk/ in the UK (n = 41 935). M3 
Global Research is a research company with 
a focus on health professionals and has the 
largest global International Organization 
for Standardization-certified physician 
community in the world. GPs were eligible 
if they were working in England at the time 
the study took place. M3 Global Research 
randomly invited GPs to the study. GPs were 
offered an industry-standard honorarium 
(£15 per GP) based on the length of the 
survey. 
Consenting GPs were provided with a 
hypothetical vignette for the potential use 
of a FIT in primary care as a point-of-
care test to rule out CRC in patients with 
symptoms that would normally qualify them 
to be referred through the 2WW pathway. 
Responders were told that FIT as a rule-out 
test would miss a very low number of CRCs, 
comparable to that of a colonoscopy, and 
‘... having a very high negative predictive 
value and minimal false negatives’. No 
detailed statistical information on test 
How this fits in
There is an increase in demand for 
colonoscopies, which could have a negative 
impact on the urgent referral timeline — 
2-week wait (2WW) — applied in England. A 
faecal immunochemical test (FIT) with a low 
or undetectable faecal haemoglobin could 
be used as a triage test in primary care to 
rule out colorectal cancer and significantly 
reduce the number of unnecessary 
colonoscopies among patients who are 
symptomatic. The findings presented here 
indicate that only just over one-third of 
GPs across England would prefer to use 
a FIT over a referral to the 2WW pathway 
with a diagnostic colonoscopy to rule out 
suspected lower gastrointestinal cancers 
among patients with symptoms; even 
among GPs who perceived FITs to be 
accurate, more than half would still prefer a 
2WW over a FIT. Initiatives to implement the 
FIT in primary care as a rule-out test need 
to be accompanied by efforts to improve 
GPs’ perception of test accuracy, as well 
as addressing concerns about increased 
consultation time and other implementation 
or organisational issues. 
Box 1. Guidance summary for suspected colorectal cancer
1. [NG125] Refer adults using a suspected cancer pathway referral (for an appointment within 2 weeks) for colorectal cancer if:
•  they are aged ≥40 years with unexplained weight loss and abdominal pain; or
•  they are aged ≥50 years with unexplained rectal bleeding; or
•  they are aged ≥60 years with:
•  iron-deficiency anaemia; or
•  changes in their bowel habit; or
•  tests show occult blood in their faeces.
2.  [NG125] Consider a suspected cancer referral pathway referral (for an appointment within 2 weeks) for colorectal cancer in adults with a rectal or abdominal mass.
3.  [NG125] Consider a suspected cancer referral pathway referral (for an appointment within 2 weeks) for colorectal cancer in adults aged <50 with rectal bleeding and 
any of the following unexplained symptoms or findings:
• abdominal pain;
• change in bowel habit;
• weight loss;
• iron-deficiency anaemia.
4.  [DG3015] The OC-Sensor, HM-JACKarc, and FOB Fold quantitative faecal immunochemical tests are recommended for adoption in primary care to guide referral for 
suspected colorectal cancer in people without rectal bleeding who have unexplained symptoms but do not meet the criteria for a suspected cancer pathway referral 
outlined in section 1, 2, and 3 [July 2017].
•  Results should be reported using a threshold of 10 mg of haemoglobin per gram of faeces. Companies should provide advice about the performance 
characteristics of the assays to laboratories, and ensure standardisation of results.
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specificity or sensitivity was provided; this 
was done to avoid confusion relating to 
different uses of the FIT and the lack of 
recommendations for patients with high-
risk symptoms. Instead, the focus was 
on the comparison with a colonoscopy 
because, if implemented, a FIT will be 
used as an alternative to the 2WW referral 
pathway. The vignette was evaluated by the 
research team for its consistency, accuracy, 
and relevancy. Detailed information is 
available from the authors on request. 
Measures
GP characteristics. GP characteristics were 
included based on previous research.24 GPs 
provided: 
• age (categorised in bands);
• sex;
• years of experience as an active GP;
• role in their practice;
• engagement in implementation/budget 
planning;
• role as a cancer lead;
• engagement in research; and
• practice size (number of registered 
patients and GPs working at the practice).
They also indicated the number of 2WW 
referrals they had made over the previous 
12 months.
Using a FIT in primary care. GPs were 
asked to choose their preferred pathway 
for patients with high-risk CRC symptoms, 
from the following options: 
• ask the patient to complete a FIT to rule 
out CRC before completing the 2WW 
referral; or
• implement the 2WW referral for 
suspected CRC (no FIT).
They were also asked ‘How accurate do you 
think the FIT is as point-of-care test to rule 
out CRC compared to a colonoscopy?’ Each 
item was measured on a 4-point scale: very 
accurate, quite accurate, not very accurate, 
not at all accurate; unsure was also included 
as an additional response option.
GPs’ perceived confidence around 
discussing the benefits and harms of FIT with 
patients was measured. Two items  assessed 
GPs confidence of discussing negative and 
positive FIT results respectively. Each item 
was measured on a 4-point scale: very 
accurate, quite accurate, not very accurate, 
not at all accurate; unsure was also included 
as an additional response option. 
GPs were asked to consider to what 
extent they believed patients would benefit 
from completing a FIT compared with 
having a colonoscopy, and whether they 
would benefit from using a FIT as a rule-in 
or rule-out test. They were also asked about 
their beliefs about the practicalities of the 
FIT, and about their role in implementing a 
FIT in primary care; this last was measured 
Table 1. GP characteristics
 Study population  Estimated GPs 
Characteristic (n = 1024), n (%) in England, 2017,a n (%)
Age in years 
 ≤35 225 (22.00)  8374 (21.20) 
 36–45 453 (44.24) 12 827 (32.50) 
 46–55 217 (21.20) 10 673 (27.00) 
 ≥56  129 (12.60) 7637 (19.30)
Sex 
 Male 545 (53.22) 17 937 (45.20) 
 Female 479 (46.78) 21 755 (54.80)
Employment status 
 Trainee 40 (3.91)  
 Full time 283 (27.64)  
 Part time 265 (25.88)  
 Locum 163 (15.92)  
 Partner 261 (25.49)  
 Other 12 (1.17) 
Geographical region 
 London 196 (19.14) 7592 (10.49) 
 Midlands and East of England 188 (18.36) 12161 (28.68) 
 South of England 265 (25.88)  10702 (25.25) 
 North of England 375 (36.62) 11934 (28.15)
Experience in years 
 <10 477 (46.58 ) 
 ≥10 547 (53.42)
Has a role in budget setting 
 No 787 (76.86) 
 Yes 237 (23.14)
Has a specialism 
 No 762 (74.41) 
 Yes 262 (25.59)
Actively involved in research 
 No 891 (87.01) 
 Yes 133 (12.99)
Patients registered at practice 
 <5000  173 (16.89) 
 5000–10 000 390 (38.09) 
 >10 000 461 (45.02)
GPs working in practice 
 <5 306 (29.88) 
 5–10 557 (54.39) 
 >10 161 (15.72)
CRC 2WW referrals in the previous 12 months 
 <5 153 (14.94) 
 5–10 440 (42.97) 
 >10 431 (42.09)
… continued 
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using 5 items. Each item was measured 
with a 4-point scale (‘strongly agree’, 
‘agree’, ‘disagree’, and ‘strongly disagree’) 
and included ‘don’t know’.
Responders were asked whether they 
were aware of the uses of FIT as a rule-
in test for patients at low risk of having 
CRC, and its use as a rule-out test among 
patients at high risk of having CRC. Previous 
experience of using a faecal occult blood 
test (FOBT) or FIT in accordance with the 
NICE guidelines was measured. 
GPs were presented with three categories 
that included several factors relating to 
the test, their organisational culture, and 
implementation of the FIT in primary 
care. They were asked to choose the most 
important category and to rate the top 
three most important factors that they, 
personally, think are important if FIT is 
implemented as a rule-out test. 
Statistical analysis
For ease of interpretation, responses were 
dichotomised, by combining ‘strongly 
agree’ and ‘agree’ versus ‘strongly 
disagree’, ‘disagree’, and unsure/don’t 
know. Descriptive statistics were used to 
demonstrate GP characteristics, along with 
a broad description of their attitudes and 
beliefs towards the implementation of a FIT. 
The frequency of the top-ranked items was 
used to order the importance of each factor 
relating to the implementation of a FIT in 
primary care. Only the top-ranked factor 
was explained in detail; information on the 
other factors is available from the authors 
on request. 
Unadjusted logistic regression analyses 
were used to identify the potential factors 
associated with GPs’ preference to use a 
FIT as a rule-out test in primary care. 
The unadjusted odds ratios (ORs) and 
confidence intervals (95% CIs) are available 
from the authors on request. A final adjusted 
multivariable logistic regression model was 
used to test for all the factors that were 
identified in univariate regression analyses 
testing associated with the preference for 
using a FIT in primary care for patients 
who have high-risk CRC symptoms, as 
opposed to the 2WW referral without a FIT. 
The significance level for our analysis was 
P<0.05. All analyses were conducted using 
Stata (version 14.0).
RESULTS
Population characteristics
Of 14 100 invitees, 1351 (9.6%) GPs 
responded to the invitation during the data-
collection period over 4 weeks. Of those, 
209 started the survey but did not complete 
it and 118 were excluded because they did 
not qualify or had completed this survey on 
a previous occasion. In total, 1024 GPs from 
England successfully completed the survey; 
this equates to 7.3% of the total number 
of invitees. Table 1 gives an overview of GP 
characteristics. 
Of the 1024 responders, 42.2% (n = 432) 
were aware of the use of a FIT as a rule-in 
test for patients with low-risk symptoms, 
but only 23.0% (n = 236) were aware that 
a FIT may also be used as a rule-out test 
to exclude CRC. Approximately half of the 
GPs (54.4%) used an FOBT for patients with 
low-risk symptoms (n = 558) in line with 
national guidance; only 10.0% (n = 102) had 
used a FIT since the guidance update of 
August 2017. 
Use of FIT as a rule-out test
In total, 35.6% of responders (n = 365) 
reported that they would prefer to use a 
FIT as a rule-out test compared with 64.4% 
(n = 659), who stated that they would prefer 
the 2WW referral without a FIT. Table 2 
outlines the fully adjusted analyses, which 
showed that responders were more likely to 
prefer FIT if they: 
• were aged 36–45 years (OR 1.59, 95% 
CI = 1.04 to 2.44); 
• were aged 46–55 years (OR 1.99, 95% 
CI = 1.14 to 3.47); 
• agreed that a FIT is highly accurate to 
rule out CRC (OR 1.63, 95% CI = 1.16 to 
2.29);
• were confident discussing the benefits of 
a FIT (OR 2.15, 95% CI = 1.46 to 3.16); and 
• believed that patients would benefit 
from completing a FIT as opposed to a 
colonoscopy (OR 2.02, 95% CI = 1.46 to 
2.79).
Table 1 continued. GP characteristics
Aware of FIT as a rule-in test 
 No 592 (57.81) 
 Yes 432 (42.19)
Aware of FIT as a rule-out test 
 No 788 (76.95) 
 Yes 236 (23.05)
Have used FOBT in line with NG125 
 No 466 (45.51) 
 Yes 558 (54.49)
Have used FIT in line with DG3015 
 No 922 (90.04) 
 Yes  102 (9.96)
aGeneral and Personal Medical Services, England High Level March 2017, Provisional Experimental Statistics.25 
2WW = 2-week wait. CRC = colorectal cancer. FIT = faecal immunochemical test. FOBT = faecal occult blood test. 
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Table 2. Factors associated with GPs’ preference to use FIT over 2WW
 Test
 2WW, n (%) FIT, n (%) Adjusted OR 95% CI
Overall 659 (64.0)  365 (35.6)
GP characteristics 
Age, years 
 ≤35  164 (72.9) 61 (27.1) Ref. 
 36–45 288 (63.6) 165 (36.4) 1.59 1.04 to 2.44a 
 46–55 126 (58.1) 91 (41.9) 1.99 1.14 to 3.47a 
 ≥56  81 (62.8) 48 (37.2) 1.47 0.78 to 2.78 
Years active as a GP 
 <10 326 (68.3) 151 (31.7) Ref. 
 ≥10 333 (60.9) 214 (39.1) 1.00 0.68 to 1.47
CRC 2WW referrals in the last year 
<5 88 (57.5) 65 (42.5) Ref. 
5–10 266 (60.5) 174 (39.5) 0.90 0.59 to 1.36 
>10 305 (70.8) 126 (29.2) 0.62 0.40 to 0.94a
FIT awareness and previous experience 
Previous experience using FIT for low-risk patients 
 No 316 (67.8) 150 (32.2) Ref. 
 Yes 343 (61.5) 215 (38.5) 1.08 0.81 to 1.45 
Perceived test accuracy 
 Not at all, not very, unsure 284 (78.9) 76 (21.1) Ref. 
 Quite, very 375 (56.5) 289 (43.5) 1.63 1.16 to 2.29b
Confidence discussing FIT with high-risk patients 
Confidence discussing benefits 
 Not at all, not very, unsure 438 (78.5) 120 (21.5) Ref. 
 Quite, very 221 (47.4) 245 (52.6) 2.15 1.46 to 3.16b 
Confidence discussing harms 
 Not at all, not very, unsure 439 (73.0) 162 (27.0) Ref. 
 Quite, very 220 (52.0) 203 (48.0) 0.98 0.68 to 1.41 
Confidence discussing negative results 
 Not at all, not very, unsure 360 (75.5) 117(24.5) Ref. 
 Quite, very 299 (54.7) 248 (45.3) 1.09 0.76 to 1.55 
Confidence discussing positive results 
 Not at all, not  218 (75.5) 57 (20.7) Ref. 
 Quite, very 441 (58.9) 308 (41.1) 1.08 0.72 to 1.62
Beliefs about patients’ experience and thoughts about FIT 
Patients would benefit from completing FIT compared with colonoscopy 
 Strongly disagree, disagree 365 (79.2) 96(20.8) Ref. 
 Agree, strongly agree 294 (52.2) 269 (47.8) 2.02 1.46 to 2.79a 
Patients will prefer FIT as a rule in test of CRC 
 Strongly disagree, disagree 257 (72.8) 96 (27.2) Ref. 
 Agree, strongly agree 402 (59.9) 269 (40.1) 1.05 0.75 to 1.47 
Patients will prefer FIT as a rule-out test 
 Strongly disagree, disagree 215 (78.5) 59 (21.5) Ref. 
 Agree, strongly agree 444 (59.2) 306 (40.8) 1.25 0.85 to 1.84 
Patients will perceive the test to be easy to complete at home  
 Strongly disagree, disagree 88 (73.3) 32 (26.7) 
 Agree, strongly agree 571 (63.2) 333 (36.8) 0.93 0.57 to 1.53
Beliefs about GPs’ role in FIT implementation 
I believe that implementation of FIT in Primary care is a legitimate part of my role 
 Strongly disagree, disagree 244 (79.7) 62 (20.3) Ref. 
 Agree, strongly agree 415 (57.8) 303 (42.2) 1.13 0.74 to 1.73 
I can easily integrate FIT into my existing work with patients who present with high-risk symptoms 
 Strongly disagree, disagree 316 (76.3) 98 (23.7) Ref. 
 Agree, strongly agree 343 (56.2) 267 (43.8) 1.19 0.84 to 1.71 
There is a strong need for FIT to be implemented in primary care as a point of care test for ruling out cancer 
 Strongly disagree, disagree 287 (78.2) 80 (21.8) Ref. 
 Agree, strongly agree 372 (56.6) 285 (43.4) 1.17 0.79 to 1.71 
I will need a longer consultation to be able to discuss why the patient will need to complete FIT 
 Strongly disagree, disagree 201 (55.5) 161 (44.5) Ref. 
 Agree, strongly agree 458 (69.2) 204 (30.8) 0.61 0.44 to 0.83a
aP<0.05. bP<0.005. 2WW = 2-week wait. CRC = colorectal cancer. FIT = faecal immunochemical test. OR = odds ratio.
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In contrast, beliefs about longer 
consultation time (OR 0.61, 95% CI = 0.44 
to 0.83) and having >10 CRC 2WW referrals 
in the previous year (OR 0.62, 95% CI = 0.40 
to 0.94) were negatively associated with 
preferring a FIT over the 2WW referral. 
Early adoption of FIT as a rule-out test in 
primary care
Of the responders, 60.5% (n = 620) stated 
that test characteristics would be the most 
important factor in their decision to use 
a FIT if it is implemented in primary care; 
organisational culture and implementation 
characteristics were only endorsed by 
14.5% (n = 148) and 25.0% (n = 256) of 
the responders, respectively. Among test 
characteristics, 35.3% ranked the number 
of false negatives (n = 361) as the main 
factor that would encourage them to 
ask patients with high-risk symptoms to 
complete a FIT; this was followed by 25.3% 
(n = 259), who ranked the number of true 
positives, and 15.1% (n = 155) who cited the 
number of true negatives (Figure 1).
DISCUSSION
Summary
When consulting with patients with high-
risk symptoms, only just over one-third of 
GPs across England would prefer to use 
a FIT to rule out CRC over referral to the 
2WW pathway for a diagnostic colonoscopy; 
they highlighted the relative importance 
of test-specific information for the early 
adoption of a FIT in primary care. GPs’ 
likelihood of preferring a FIT increased 
if they believed the accuracy of the test 
to be high, were confident discussing the 
benefits with the patients, and strongly 
agreed that the patients would benefit from 
a FIT compared with having a colonoscopy. 
GP responders were less likely to prefer 
the FIT if they had had >10 2WW referrals 
for CRC in the previous 12 months and 
thought the consultations would be longer 
if FIT was implemented. The fact that the 
vast majority of GPs had not asked their 
patients to complete a FIT before means 
that their GP responder concerns about 
longer consultation times were not based 
in actual experience. These concerns 
present an anticipated barrier that should 
be considered by commissioners, who will 
provide pathways to FIT implementation in 
primary care. GPs who agreed that it is part 
of their role to support the implementation 
of a FIT, and that there is a strong need for 
a FIT, were no more likely to prefer the test 
than those who did not. Furthermore, there 
was no association between FIT preference 
and awareness of the use of FIT in primary 
care for patients classified as ‘low-risk but 
not no risk’.
Strengths and limitations 
As a relatively large, nationally 
representative sample, this survey study 
was able to highlight the barriers and 
facilitators of implementing the FIT in 
primary care for patients who may present 
with high-risk CRC symptoms. However, 
there were some notable limitations. 
Despite the large number of responders, 
the actual survey response rate was <10%, 
thereby restricting the generalisability of the 
findings; however, comparable response 
rates have been observed in previous 
studies based on primary care using similar 
methodologies.24,26
It is also worth noting that GPs only 
expressed their preference in the absence of 
clinical recommendations. The awareness 
of different uses of a FIT in symptomatic 
context prior to the survey was low; as 
such, the study was designed with caution 
to avoid confusion that might arise from the 
different thresholds and recommendations 
that exist for the different uses of a FIT.15,18,21 
Most GPs in this survey prioritised test 
characteristics — and, specifically, test 
accuracy — when considering whether 
to use a FIT in patients with high-risk 
symptoms. However, it must be noted that, 
even among GPs who perceived the FIT to 
be accurate, only 35.6% would prefer to use 
it over a 2WW referral. This highlights that, 
even if current research projects showed 
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Figure 1. Factors cited by GPs (n = 1024) in their 
decision to use a faecal immunochemical test in 
primary care to test for colorectal cancer in patients 
with high-risk symptoms.
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that a FIT could rule out cancer with 100% 
accuracy,17,18 more work would need to 
be done to overcome other anticipated 
barriers. 
Perceptions of FIT might be further 
confounded by a tendency to overemphasise 
test sensitivity (as revealed by the relative 
importance that GPs attributed to true 
positives), despite the fact that, in the 
context of a rule-out test, specificity (that 
is, true negatives and false positives) is 
equally important, particularly with future 
sustainability of endoscopy services in 
mind. One potential way to understand 
whether accuracy is the key factor in GPs’ 
decisions to use FIT over 2WW would be 
using discrete-choice studies, which will 
investigate test preferences based on 
FIT statistics (threshold, sensitivity, and 
specificity) and other test attributes, such 
as changes in consultation times.
At present, there are very little data on the 
proportion of test kits that are successfully 
completed and returned in the diagnostic 
context. Thus it is important to use insights 
from studies into barriers to completing 
similar tests for CRC screening to inform 
future research into FIT implementation 
as a diagnostic test. Specifically, it has 
been shown that non-white ethnic groups, 
people with low health literacy, non-English 
speakers, and those who do not engage 
with the information are less likely to 
complete the test kit.27–30 As the FIT, if 
implemented as a rule-out test, would be 
aimed at patients with high-risk symptoms, 
it is imperative to address GPs’ concerns 
about their patients’ ability to complete the 
test kits and have appropriate safety-netting 
activities (for example, text-message 
reminders and follow-up appointments) in 
place in both primary and secondary care. 
Implications for research and practice 
As the FIT will be implemented in CRC 
screening in England,31 there will be 
potentially three different clinical contexts 
(screening population, and patients with 
low- and high-risk symptoms) in which 
immunochemical testing is used. Each 
context could vary on a number of aspects; 
most notably, clinical thresholds used to 
determine follow-up referrals. Given that 
GPs’ awareness of using a FIT in both rule-
in and rule-out contexts was low among 
the survey responders, in future, particular 
attention should be paid to raising GPs’ 
awareness of different thresholds used 
in different contexts, as well as patients’ 
experience of using a FIT and their 
understanding of the purpose of a FIT in all 
clinical contexts.
This national survey suggests that a 
majority of GPs would prefer to use the 
current default test. Concerns about 
additional pressures on consultation time 
should be addressed in anticipation of any 
changes to NICE’s guidelines. Qualitative 
interviews with GPs might gain additional 
insights about potential barriers and identify 
the most effective ways of supporting 
implementation of a FIT as a rule-out test 
for CRC. The current implementation of 
NICE guidelines for patients with low-risk 
symptoms will offer further observational 
evidence.
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